News Upcoming Events Publications

Sosei Pays GBP 35 Million for an Equity Stake and Acquisition Option Agreement in MiNA TherapeuticsPotential acquisition tied to clinical milestones of lead candidate MTL-CEBPA, a novel small activating RNA therapeutic in Phase 1/2a development in advanced liver cancer

Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) and MiNA Therapeutics Limited (“MiNA”) announced today that the companies have entered into a definitive agreement under which Sosei will make an investment in and acquire an exclusive option to potentially acquire MiNA Therapeutics, a private UK biopharmaceutical company and pioneer in RNA activation therapeutics (small activating […]

More Info
View the press release here

MiNA Therapeutics Presents Data Demonstrating Survival Benefit of MTL-CEBPA in Animal Model of Liver Failure at AASLD Liver Meeting

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the presentation of pre-clinical data on its MTL-CEBPA program in which the compound was shown to improve survival in a rat model of liver failure. MTL-CEBPA is the first development candidate to emerge from MiNA’s RNA activation platform and is currently being evaluated in a […]

More Info
View the press release here

MiNA Therapeutics Announces Presentation of Pre-Clinical Data Supporting On-Target Mechanism of Action of Clinical Candidate MTL-CEBPA

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the presentation of data supporting the on-target mechanism of action of drug candidate MTL-CEBPA. MTL-CEBPA is the first development candidate to emerge from MiNA’s RNA activation platform and is currently being evaluated in a Phase I clinical study in patients with liver cancer. The data […]

More Info
View the press release here

MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA in Patients with Liver Cancer

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the initiation and first patient treated in the OUTREACH Phase I clinical study of their lead program, MTL-CEBPA, in severe liver cancer. The study is the first-in-human trial of a small activating RNA (saRNA) and is designed to assess the safety and tolerability of MTL-CEBPA, […]

More Info
View the press release here

MiNA Therapeutics Granted US Patent Covering Small Activating RNAs Targeting the CEBPA Gene

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced that the United States Patent and Trademark Office (USPTO) has granted the first in a series of patents filed by MiNA Therapeutics protecting its CEBPA drug development program (US Patent Number 9,284,553). The patent covers the company’s lead program MTL-CEBPA, currently in preclinical development for […]

More Info
View the press release here

MiNA Therapeutics Announces AASLD Liver Meeting Presentation on Lead Program Demonstrating Reversal of Liver Failure in Animal Model

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the presentation of pre-clinical data on its MTL-CEBPA program in which the compound was shown to improve several markers of liver function in a rat model of liver failure. MTL-CEBPA is the first development candidate to emerge from MiNA’s RNA activation platform and the company […]

More Info
View the press release here

David Blakey Ph.D. joins MiNA Therapeutics as Chief Scientific Officer

MiNA Therapeutics, the pioneer in RNA activation therapeutics, today announced the appointment of David Blakey Ph.D. as Chief Scientific Officer. Dr. Blakey will lead the Company’s research and development activities.   “David brings to MiNA a depth of scientific expertise that will be critical in advancing our pipeline of innovative RNA-based therapies,” said Robert Habib, […]

More Info
View the press release here

Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-based Therapeutics

Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA’s proprietary oligonucleotides and […]

More Info
View the press release here

European Patent Office Grants Broad RNAa Patent from Corey Estate Exclusively Licensed by MiNA Therapeutics

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that the European Patent Office (EPO) has granted a patent in the Corey patent estate (EP Patent Number 2641970). This patent stems from the pioneering RNAa research performed by the Corey lab at the University of Texas Southwestern Medical Center, which was exclusively licensed by […]

More Info
View the press release here

MiNA Completes Exclusive License Agreement with University of California San Francisco

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today that it has completed an exclusive license agreement with The Regents of the University of California relating to intellectual property rights developed by the Li lab at UC San Francisco (UCSF). The exclusive license complements MiNA’s fundamental intellectual property portfolio that broadly covers RNAa therapeutics, […]

More Info
View the press release here

Study published in Hepatology demonstrates ability of saRNA to improve liver function and inhibit carcinogenesis in vivo

MiNA Therapeutics, a biotechnology company developing RNA for transcriptional gene activation, announced today that its academic co-founders published a study in Hepatology demonstrating that saRNA therapeutics induced in vivo production of mRNA and proteins to improve liver function and inhibit tumour burden in a rat model of hepatocellular carcinoma (HCC). The research provides pre-clinical proof-of-concept […]

More Info
View the press release here